TY - JOUR
T1 - Rhabdomyolysis associated with long-term treatment of esomeprazole
AU - Nishikawa, Jun
AU - Hosokawa, Ayumu
AU - Fuchino, Mayo
AU - Takatori, Shunsuke
AU - Iwamoto, Masaya
AU - Kashii, Yoshiro
AU - Bando, Tadashi
AU - Shimizu, Tetsuro
AU - Minemura, Masami
AU - Sugiyama, Toshiro
N1 - Publisher Copyright:
© 2018 Japanese Society of Gastroenterology. All rights reserved.
PY - 2018
Y1 - 2018
N2 - Proton pump inhibitors (PPIs) have been widely used in the treatment of gastroesophageal reflux disease and peptic ulcer disease. Although they have a potent acid suppressive effect and excellent efficacy in acid-related diseases, PPI-induced rhabdomyolysis has been reported. Here, we report the case of a patient with reflux esophagitis who developed rhabdomyolysis after esomeprazole treatment. A 67-year-old man with reflux esophagitis who had started esomeprazole treatment for the preceding 10 months complained of back and limb fatigue and myalgia. His serum creatinine kinase (CK) level was markedly elevated, and CK isozyme exhibited an MM pattern. He was diagnosed with rhabdomyolysis induced by esomeprazole. The cessation of esomeprazole rapidly improved his symptoms, and the serum CK level was normalized within 16 days. PPI-induced rhabdomyolysis is a rare complication. In most cases, PPI-induced rhabdomyolysis occurs within 3 months after starting PPIs. However, rhabdomyolysis occurred at 10 months after starting esomeprazole treatment in our patient Early diagnosis of PPI-induced rhabdomyolysis is required even in long-term PPI users.
AB - Proton pump inhibitors (PPIs) have been widely used in the treatment of gastroesophageal reflux disease and peptic ulcer disease. Although they have a potent acid suppressive effect and excellent efficacy in acid-related diseases, PPI-induced rhabdomyolysis has been reported. Here, we report the case of a patient with reflux esophagitis who developed rhabdomyolysis after esomeprazole treatment. A 67-year-old man with reflux esophagitis who had started esomeprazole treatment for the preceding 10 months complained of back and limb fatigue and myalgia. His serum creatinine kinase (CK) level was markedly elevated, and CK isozyme exhibited an MM pattern. He was diagnosed with rhabdomyolysis induced by esomeprazole. The cessation of esomeprazole rapidly improved his symptoms, and the serum CK level was normalized within 16 days. PPI-induced rhabdomyolysis is a rare complication. In most cases, PPI-induced rhabdomyolysis occurs within 3 months after starting PPIs. However, rhabdomyolysis occurred at 10 months after starting esomeprazole treatment in our patient Early diagnosis of PPI-induced rhabdomyolysis is required even in long-term PPI users.
UR - http://www.scopus.com/inward/record.url?scp=85046545757&partnerID=8YFLogxK
U2 - 10.11405/nisshoshi.115.299
DO - 10.11405/nisshoshi.115.299
M3 - 学術論文
C2 - 29526982
AN - SCOPUS:85046545757
SN - 0446-6586
VL - 115
SP - 299
EP - 304
JO - Journal of Japanese Society of Gastroenterology
JF - Journal of Japanese Society of Gastroenterology
IS - 3
ER -